What is the Share Price of Godavari Drugs Ltd?

Godavari Drugs Ltd share price is ₹88.02 As on 09 May, 2025|10:08

Home
>
Stocks
>
Godavari Drugs Ltd

Godavari Drugs Ltd Share Price

Q: What is the Market Cap of Godavari Drugs Ltd?

The Market Cap of Godavari Drugs Ltd is ₹67.8 As on 09 May, 2025|10:08

Q: What is PE Ratio of Godavari Drugs Ltd?

The P/E ratio of Godavari Drugs Ltd is 11 As on 09 May, 2025|10:08

Q: What is PB Ratio of Godavari Drugs Ltd?

The PB ratio of Godavari Drugs Ltd is 1.59 As on 09 May, 2025|10:08

₹ 0.00 0 (0%)
Updated on 01-01-1970 5:30 AM

Stock Rating

BSE

Pros 1

Cons 7

Godavari Drugs Ltd Price Performance

Day's Low
₹0

Day's High
₹0

₹ 0

52-w low
₹0

52-w high
₹0

Day's open
₹0
Previous close
₹0
VWAP
₹0
Lower price band
₹0
Upper price band
₹0

Today's Market Action

Its last traded stock price on BSE was 88.02 down by -2.20%. The total volume of shares on NSE and BSE combined was 10 shares. Its total combined turnover was Rs 0.00 crores.

Godavari Drugs Ltd Medium and Long Term Market Action

The stock price of Godavari Drugs Ltd is down by -100% over the last one month. Don't forget to check the full stock price history in the table below.

Godavari Drugs Ltd Fundamentals

Market Cap (Cr): 67.8
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Godavari Drugs Ltd Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Godavari Drugs Ltd Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Godavari Drugs Ltd

Data not available.

Godavari Drugs Ltd FAQ's

What is Share Price of Godavari Drugs Ltd?

What is the Market Cap of Godavari Drugs Ltd?

What is PE Ratio of Godavari Drugs Ltd?

What is PB Ratio of Godavari Drugs Ltd?

What is the CAGR of Godavari Drugs Ltd?

How to Buy Godavari Drugs Ltd Share?

Can I buy Godavari Drugs Ltd from Samco?

How do I buy Godavari Drugs Ltd from Samco?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

Great Cash Conversion of Profits
The business has a great cash conversion ratio since it is able to convert a signifant portion of operating earnings of 128.57% into operating cash flow. This implies a great working capital cycle and large cash flows for either funding growth or dividends. This shall positively impact shareholder returns.

Cons

Low Sustainable RoE
The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
Low Return on Capital Employed
The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
Low Interest Coverage
The company has a very low Interest coverage ratio of 2.60 times which implies that a large portion of operating profits are getting attributed to payment of interest to debtholders. This leaves lower earnings and cash flows for equity shareholders which is negative for returns.
Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Low Pricing Power & High Competition
The business has extremely low pricing power and is vulnerable to competitive pressure which can significantly impact shareholder returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 158 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
Poor Corporate Governance
The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(09/05/2025)

102

Margin of Safety Index: High

0.00%

0.00% People are bullish about Godavari Drugs Ltd

100.00%

100.00 % People are bearish about Godavari Drugs Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %